Colozo 145 mcg (Linaclotide)

Colozo 145 mcg is a prescription medication formulated to manage chronic constipation and irritable bowel syndrome with constipation (IBS‑C) in adult patients. Manufactured by Dr Reddy’s Laboratories Ltd, the product is supplied in sealed bottles containing either 10, 20, or 40 capsules, each capsule delivering 145 micrograms of the active ingredient linaclotide. The medication is packaged for oral administration and is intended for once‑daily use. Shipping typically occurs within six to fifteen days, offering patients a reliable option for ongoing treatment. This overview provides a concise yet comprehensive look at the product’s specifications, therapeutic purpose, and logistical details for healthcare consumers seeking a trustworthy solution for bowel regularity.

What is Colozo 145 mcg

Colozo 145 mcg contains linaclotide, a synthetic 14‑amino‑acid peptide that acts as a guanylate cyclase‑C (GC‑C) agonist. As a GC‑C receptor stimulator, linaclotide enhances intracellular cyclic guanosine monophosphate (cGMP) levels, which in turn promotes intestinal fluid secretion, accelerates transit, and reduces visceral sensitivity. The drug is classified pharmacologically as a chloride channel activator and is chemically distinct from other laxatives or prokinetics. Its molecular structure is engineered to resist enzymatic degradation in the gastrointestinal tract, ensuring consistent delivery to the distal small intestine and colon where it exerts its primary effect. Understanding the mechanism of action helps clinicians and patients appreciate why Colozo is prescribed for specific gastrointestinal disorders.

Uses and Benefits

Colozo is indicated for the treatment of chronic constipation of unknown origin and for the management of irritable bowel syndrome with constipation (IBS‑C) in adults. Clinical studies have demonstrated that regular use of linaclotide leads to a statistically significant increase in complete spontaneous bowel movements (CSBMs) compared with placebo, as well as improvements in stool frequency, consistency, and associated abdominal discomfort. Patients often report a reduction in bloating, urgency, and the sensation of incomplete evacuation. Beyond symptom relief, the medication may contribute to better quality of life by decreasing healthcare utilization related to constipation‑related complications. Its once‑daily dosing simplifies adherence, and the availability of multiple pack sizes allows clinicians to tailor supply to individual patient needs.

How It Works

The pharmacological activity of linaclotide begins when it binds to the GC‑C receptor located on the luminal surface of intestinal epithelial cells. This binding triggers an intracellular cascade that elevates cGMP, leading to activation of the CFTR (cystic fibrosis transmembrane conductance regulator) chloride channel and subsequent secretion of chloride and water into the intestinal lumen. The increased luminal fluid softens stool and facilitates its passage through the colon. Additionally, the rise in cGMP modulates sensory nerve pathways, diminishing the perception of pain and discomfort associated with constipation. The dual action—enhanced fluid secretion and reduced visceral hypersensitivity—makes linaclotide a distinctive therapeutic option among bowel agents.

Dosage Guidelines

Colozo is administered as one capsule taken orally once daily, preferably at the same time each day. The capsule should be swallowed whole with a sufficient amount of water and may be taken with or without food; however, patients are advised not to crush or chew the tablet to preserve the integrity of the coating. The standard dosage for most adult patients is 145 mcg per day. In patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), a reduced dose of 72 mcg once daily may be considered after clinical evaluation. Treatment duration is not strictly defined; clinicians typically assess therapeutic response after several weeks and may continue therapy based on ongoing benefit and tolerability. Patients should be instructed to store the medication at room temperature, away from moisture and heat, and to keep the bottle tightly closed.

Side Effects

Like all pharmaceutical agents, Colozo may be associated with adverse effects, most of which are mild to moderate and transient. The most commonly reported side effects include diarrhea, abdominal pain, flatulence, and headache. Diarrhea can range from loose stools to more frequent watery movements; if severe or persistent, patients should contact their healthcare provider. Less frequent but clinically relevant events comprise nausea, vomiting, and dizziness. Rarely, patients may experience allergic reactions such as rash, pruritus, or, in extreme cases, anaphylaxis. It is essential for patients to monitor their symptoms and report any unexpected or worsening conditions to a qualified medical professional promptly.

Warnings and Precautions

Colozo is contraindicated in individuals with known or suspected mechanical gastrointestinal obstruction, bowel perforation, or toxic megacolon. Patients with a history of severe renal or hepatic disease should undergo dose adjustment and close monitoring, as pharmacokinetic alterations may occur. The medication is not indicated for use in pediatric populations under 18 years of age, and its safety during pregnancy has not been established; therefore, it should only be used if the potential maternal benefit justifies the potential fetal risk. Concurrent use of other laxatives or medications that affect gastrointestinal motility should be reviewed with a clinician to avoid additive effects. Additionally, patients should be advised to inform their provider of any new or worsening abdominal pain, blood in the stool, or signs of dehydration.

Frequently Asked Questions

1. What condition does Colozo treat? Colozo 145 mcg is approved for chronic constipation and irritable bowel syndrome with constipation (IBS‑C) in adults. It works by increasing fluid secretion in the intestines to promote regular bowel movements.

2. How should I take Colozo? The recommended dose is one capsule daily, taken whole with water, at the same time each day. It may be taken with or without food, but should not be crushed or chewed.

3. Are there any serious side effects? The most common adverse events are diarrhea, abdominal pain, and flatulence. Rare but serious side effects include severe diarrhea leading to dehydration and allergic reactions. Seek medical attention if you experience persistent watery diarrhea, blood in the stool, or signs of an allergic reaction.

4. Can I use Colozo if I am pregnant or breastfeeding? The safety of linaclotide during pregnancy and lactation has not been fully studied. Use should only be considered if the expected benefit outweighs any potential risk, and you must discuss this with your healthcare provider.

5. Where can I find more detailed prescribing information? Detailed FDA‑approved prescribing information is available through the U.S. Food and Drug Administration website and on authoritative drug databases such as Drugs.com. For clinical references, the National Institutes of Health provides peer‑reviewed articles on GC‑C agonists.

For additional resources on gastrointestinal health, reputable consumer sites such as Mayo Clinic and MedlinePlus offer evidence‑based information that complements professional medical advice.

Related Products

• Morease 135 mg (Mebeverine)
• Omez 10 mg (Omeprazole)
• Razo 10 mg (Rabeprazole)
• Omeprazole 40 mg (Generic)
• Niltan Cream (Liquorice/Boswellia Serrata/Arbutin/Coriander Seed Oil)
• Salicylix SF Cream (Salicylic Acid)
• Salicylix SF 6% Cream (Salicylic Acid)
• Salicylix SF 12% Cream (Salicylic Acid)
• Tazzle (Tadalafil)
• Tazzle 20 mg (Tadalafil)
• Redotil (Racecadotril )
• Finast (Finasteride)